Risk factors and diagnostic biomarkers for asymptomatic immune checkpoint inhibitor-related myocarditis in patients with esophageal cancer after immunotherapy

doi:10.3748/wjg.v31.i26.106509

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 26

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1191)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

HTML

568

Figures (1-4)

Tables (1-5)

Sum=748

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

198

Sum=288

Publishing Process of This Article

Item

Count

Browse

Download

Sum=114

Jul 14, 2025 (publication date) through Aug 9, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Jul 14, 2025; 31(26): 106509
Published online Jul 14, 2025. doi: 10.3748/wjg.v31.i26.106509

Full Size Figure Download Figure

Figure 1 Tumor biomarker levels. A: Cancer antigen 125; B: Carcinoembryonic antigen; C: Squamous cell carcinoma antigen. ^aP > 0.05. CA125: Cancer antigen 125; CEA: Carcinoembryonic antigen; SCC: Squamous cell carcinoma antigen.

Citation: Liu JY, Gao DL, Cao X. Risk factors and diagnostic biomarkers for asymptomatic immune checkpoint inhibitor-related myocarditis in patients with esophageal cancer after immunotherapy. World J Gastroenterol 2025; 31(26): 106509
URL: https://www.wjgnet.com/1007-9327/full/v31/i26/106509.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i26.106509